What Your First Aesthetic Patient Consultation Should Look Like

A Step-by-Step Medico-Legal Guide for NHS Clinicians

Your first aesthetic consultation is the single most important clinical encounter in your new practice. Get it right and you build trust, manage expectations, and protect yourself legally. Get it wrong and you risk patient dissatisfaction, complaints, and regulatory exposure regardless of how technically skilled you are.

For NHS clinicians, the good news is that much of what makes a great aesthetic consultation mirrors what you already do: thorough history-taking, clear communication, documented consent, and clinical judgement. The difference is context” aesthetic patients are elective, self-funding, and may carry psychological factors that require careful assessment.

This guide walks through each stage of the consultation from a medico-legal standpoint, with reference to current GMC, NMC, and JCCP guidance.

Before You Begin: The Legal Framework   Three key principles underpin every aesthetic consultation in the UK:   Consent must be valid, informed, and personally obtained by the treating clinician. It cannot be delegated to administrative or sales staff.Every prescription for botulinum toxin must follow an in-person consultation. As of January 2025, all regulatory bodies have made their position clear that remote prescribing for aesthetic POMs is not permitted.You must assess psychological suitability before agreeing to treat. The GMC’s Cosmetic Interventions guidance requires you to consider patient vulnerability and psychological needs.

Step 1: Before the Patient Arrives — Setting Up the Consultation

A robust consultation starts before the patient walks through the door. Your booking and intake process should capture enough information to allow a productive, safe clinical encounter.

Pre-consultation checklist:

• Medical history form sent in advance. Ask about current medications (including anticoagulants, immunosuppressants), allergies, previous aesthetic treatments and outcomes, and relevant medical history (e.g. autoimmune conditions, cold sore history for perioral filler, bleeding disorders).
• Photograph consent obtained. Standardised before-and-after photography is essential for clinical records and medico-legal protection. Confirm patients consent to photographs being taken and stored.
• Privacy notice provided. Under UK GDPR, patients must be informed about how their data will be used before you collect it. Provide a privacy notice with your booking confirmation.
• Cooling-off period flagged for new patients. The GMC’s Cosmetic Interventions guidance advises that patients should be given adequate time to reflect before proceeding. Consider a policy of not treating first-time patients at the same appointment as their initial consultation.

Step 2: Opening the Consultation — Motivation and Expectations

The GMC’s guidance on cosmetic interventions is explicit: you must ask the patient why they would like to have the intervention and the outcome they hope for, before assessing whether the intervention is appropriate and likely to meet their needs.

This is not a sales conversation. It is a clinical assessment of suitability. Open questions work best:

• ‘What brings you in today, and what would you like to achieve?’
• ‘How long have you been thinking about this?’
• ‘Has anything happened recently that has made you want to address this now?’
• ‘Have you had any aesthetic treatments before? How did you find the results?’

Listen carefully. Patients who are seeking treatment because of pressure from others, who describe outcomes that are unrealistic, or who appear distressed about a feature that is barely perceptible to you, require careful further assessment before you proceed.

Screening for Body Dysmorphic Disorder (BDD)   BDD is a psychological disorder characterised by excessive preoccupation with perceived flaws in appearance that are minimal or invisible to others. It is estimated to affect between 2–13% of cosmetic patients, and individuals with BDD will not benefit from aesthetic procedures. In fact, they may deteriorate clinically following them.   Validated screening tools used in aesthetic practice include:   Cosmetic Procedure Screening Questionnaire (COPS) Body Dysmorphic Disorder Questionnaire (BDDQ) Dysmorphic Concern Questionnaire (DCQ)   If you identify features consistent with BDD — significant distress, multiple prior treatments with dissatisfaction, or preoccupation with a minor or absent flaw — do not treat. Refer to the patient’s GP with a clinical note, or signpost them to the Body Dysmorphic Disorder Foundation.

Step 3: Medical History and Contraindications

Even for apparently simple aesthetic treatments, a structured medical history is essential. This is where your NHS clinical background gives you a significant advantage over less experienced practitioners.

Area	What to Ask	Why It Matters
Medications	Anticoagulants (warfarin, DOACs, aspirin), immunosuppressants, acne medications (isotretinoin), steroids	Bruising risk, wound healing, contraindications to certain treatments
Allergies	Lidocaine, hyaluronidase, latex, prior filler reactions	Product selection and emergency preparedness
Skin conditions	Active cold sores (HSV), active acne, eczema or psoriasis at treatment site	Treatment safety and timing — active infection is a contraindication
Medical history	Autoimmune conditions, neuromuscular conditions, pregnancy or breastfeeding, bleeding disorders	Absolute and relative contraindications to botulinum toxin and fillers
Previous aesthetics	Prior treatments, products used, complications, level of satisfaction	Filler accumulation, prior adverse reactions, managing expectations
Mental health	History of anxiety, depression, eating disorders, body image concerns	BDD risk stratification and patient vulnerability assessment

Step 4: The Clinical Assessment

Before discussing any treatment plan, assess the patient clinically. This is a medical consultation, not a menu selection exercise.

• Facial assessment: Assess facial anatomy in animation and at rest. Note facial symmetry, skin quality, tissue volume, bony landmarks, and any pre-existing asymmetries. Document these: asymmetries that were present before treatment must be recorded to avoid post-treatment disputes.
• Anatomical risk stratification: Identify relevant vascular anatomy, particularly for filler treatments. Note danger zones and plan accordingly.
• Standardised photography: Take standardised frontal, oblique, and lateral photographs before every treatment. These are both a clinical tool and a medico-legal record. Ensure consistent lighting, distance, and neutral expression.
• Document baseline: Note any pre-existing conditions at the treatment site — a bruise, asymmetry, or ptosis — that could be attributed to your treatment if not recorded beforehand.

Step 5: Consent — The Medico-Legal Core of the Consultation

Valid consent in aesthetics is governed by the same legal and ethical framework as all medical consent in the UK, rooted in the Supreme Court’s ruling in Montgomery v Lanarkshire [2015] UKSC 11. The key principle: a material risk is one that a reasonable person in the patient’s position would want to know about, or that this specific patient would attach significance to.

The GMC’s Decision Making and Consent guidance (updated December 2024) states that serious harm can result if patients are not given the information they need — and time and support to understand it — to make informed decisions.

For consent to be valid in aesthetics, it must be:

• Voluntary: The patient must not be under pressure from you, your marketing, or anyone else. The GMC’s Cosmetic Interventions guidance requires you to satisfy yourself that the request is voluntary.
• Informed: You must discuss the realistic benefits, the likely outcomes, the known risks and side effects, and the alternatives (including doing nothing). Do not imply guaranteed results — the GMC states you must not falsely claim that certain results are guaranteed.
• Capacity-confirmed: The patient must have the capacity to make this decision. For adults, capacity is assumed unless there is reason to question it. Be alert to presentations that suggest impaired judgement.
• Personally obtained: The GMC is explicit: you must obtain consent yourself. It cannot be obtained by a receptionist, a sales team member, or anyone else.
• Documented: A signed consent form is evidence that consent was obtained — but it is your contemporaneous clinical notes that demonstrate the quality of the consent process. Document what you discussed, what the patient understood, and any questions they asked.

Cooling Off: Same-Day Treatment for New Patients   The GMC’s guidance on cosmetic interventions advises that patients should be given adequate time for reflection before proceeding with treatment. There is no mandated waiting period, but the guidance lists relevant factors: the invasiveness of the treatment, how much information the patient has already considered, and whether the patient is considering multiple procedures.   For first-time patients, best practice is to separate the consultation from treatment — particularly for more complex treatments or volume of filler. Where same-day treatment is appropriate (e.g., an established returning patient booking an additional area), this is a clinical decision you must be able to justify.

Step 6: Treatment Planning and Managing Expectations

Once you have completed your assessment and confirmed the patient is suitable, you are in a position to discuss a treatment plan. The plan should be led by clinical findings — not by what the patient has seen on social media or what treatments you have in stock.

• Be honest about what is achievable. Aesthetic results are not guaranteed. Facial anatomy, product behaviour, and individual healing all affect outcomes. Patients who have unrealistic expectations are at higher risk of dissatisfaction even following a technically perfect treatment.
• Discuss alternatives. The GMC requires you to tell patients about alternative interventions that could meet their needs with less risk. If a different approach — or no treatment — would serve them better, say so.
• Stage treatments where appropriate. For new patients, especially with filler, consider treating conservatively at first. Over-treatment in an initial session is one of the most common causes of patient dissatisfaction and adverse outcomes.
• Price transparency. The GMC requires you to be honest about fees before beginning any investigation or treatment. Confirm costs in writing before treatment begins.

Step 7: Prescribing — In-Person Only

Since January 2025, in-person consultations are mandatory for all prescriptions for aesthetic POMs, including botulinum toxin. Remote prescribing for aesthetic purposes — even for established returning patients — is no longer permitted under unified guidance from the GMC, NMC, and GPhC.

This means: the clinician issuing the prescription must physically examine the patient at the same appointment. A prescription cannot be issued on the basis of a video call, photographs, or a telephone consultation.

• Doctors: May prescribe botulinum toxin within their scope of practice, having personally examined the patient. They are permitted to hold and prescribe from stock.
• Independent nurse prescribers: May prescribe following in-person assessment within their scope of practice.
• Non-prescribing nurses: Require a prescribing arrangement with a supervising prescriber who must conduct their own in-person assessment of the patient.
• Dentists: May prescribe botulinum toxin as it falls within their prescribing scope, having conducted an in-person assessment.

Step 8: Record Keeping and Documentation

In aesthetics, if it is not documented, it did not happen. Your clinical notes are your primary defence in any complaint, claim, or regulatory investigation.

Every consultation record should include:

• Date, time, and duration of the consultation
• The patient’s presenting concern and stated motivation for treatment
• Relevant medical history, medications, and allergies
• Clinical findings and facial assessment
• BDD and psychological screening outcome
• Treatment plan discussed, including alternatives offered
• Risks and benefits discussed, and patient’s understanding confirmed
• Consent obtained — signed form referenced, verbal consent documented
• Products used (batch number, volume, injection sites) — essential for traceability
• Before and after photographs taken — referenced in notes
• Post-treatment advice given
• Follow-up arrangements

Under UK GDPR and the Data Protection Act 2018, private aesthetic records should be retained for a minimum of eight years after the last treatment. Ensure records are stored securely — whether electronically or in paper format — with access limited to authorised personnel.

Step 9: After the Treatment — Aftercare and Follow-Up

The consultation does not end when the patient leaves the clinic. Robust aftercare protocols protect both patient safety and your professional standing.

• Provide written aftercare instructions. Verbal advice alone is insufficient. Give every patient written post-treatment guidance covering what to expect, what to avoid, and when to contact you.
• Provide emergency contact details. Patients must be able to reach you — or a colleague — if they experience unexpected effects. This is particularly important for filler patients at risk of vascular complications.
• Schedule a follow-up. A review appointment at two to four weeks demonstrates continuity of care and gives you the opportunity to assess outcomes, address concerns, and take post-treatment photographs.
• Document any complications. If a patient reports a problem — however minor — document it contemporaneously. Notify your indemnity provider early if a formal complaint appears likely.

Know When to Say No   One of the most important skills in aesthetic practice is recognising when not to treat. You should decline to treat if:   You identify features of BDD or significant psychological vulnerabilityThe patient’s expectations are unrealistic and cannot be managed in the consultationThe treatment carries risks that outweigh the likely benefit for this patientThe patient is under 18 (strict age restrictions apply to botulinum toxin and fillers)You are not confident in your competence to perform the procedure safely   Declining to treat is a clinical decision, not a commercial failure. Your GMC, NMC, or GDC registration depends on you acting within your competence and in your patient’s best interests. Documenting your reasons for declining protects you and demonstrates sound professional judgement.

Build Your Consultation Skills from the Start   Our Foundation and Advanced Courses embed medico-legal consultation skills, consent frameworks, and patient assessment alongside clinical technique — so you are confident in both the procedure room and the consultation room from day one.

Already Practising? Convert More Consultations Into Treatments.   The Consultation Catalyst Masterclass with Dr Kamran Amjed MD teaches you how to structure consultations that build patient confidence, manage expectations effectively, and achieve a 92% consultation-to-treatment conversion rate — without compromising on clinical rigour or patient safety.

References and Further Reading

• General Medical Council. (2024, updated December 2024). Guidance for Doctors Who Offer Cosmetic Interventions.
• General Medical Council. (2020, updated December 2024). Decision Making and Consent.
• General Medical Council. (2015). Montgomery v Lanarkshire — making decisions together.
• Acquisition Aesthetics. (2025). New UK Prescribing Rules 2025: Aesthetic Law Update.
• Joint Council for Cosmetic Practitioners (JCCP). (2023). Patient Emotional and Psychological Safety Guidance.
• Hamilton Fraser. Body Dysmorphic Disorder in Aesthetics.
• Hamilton Fraser. GDPR in Aesthetics: Protecting Patient Data in Clinics.
• House of Commons Library. (2026). The Regulation of Non-Surgical Cosmetic Procedures in England.
• GMC. (2024). Communication, Partnership and Teamwork — Cosmetic Interventions.